ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO813

Discrepancy of Serum Ant-PLA2R and Podocyte PLA2R Expression in Taiwan Patients with Membranous Nephropathy

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation


  • Tu, Kun-Hua, Chang gung memorial hospital, Taoyuan, Taiwan
  • Wu, Tsai-yi, Chang Gung University, Taoyuan, Taiwan
  • Ku, Cheng-Lung, Chang Gung University, Taoyuan, Taiwan

Anti-phospholipase A2 receptor (PLA2R) autoantibodies could be found in 60~85% patients with idiopathic membranous nephropathy, first discovered in 2009. Enhanced expression of podocyte PLA2R protein in these patients was also postulated later. There are some patients, however, have serum anti-PLA2R antibodies only without enhanced expression of podocyte PLA2R protein, vice versa. Currently, patient with membranous nephropathy have one of each will be diagnosed as PLA2R-associated membranous nephropathy. The mechanism of this discrepancy existing is not clearly known yet. To date, there are few articles reporting prevalence of serum anti-PLA2R and podocyte PLA2R expression in Taiwan patient with membranous nephropathy. We conduct a study to investigate this issue.


This investigation was prospectively performed in a tertiary hospital. From 2016/8-2018/5 period, patients with biopsy-proved membranous nephropathy will received blood test of plasma anti-PLA2R ELISA (Euroimmune®) before initiation of glucocorticoid or immunosuppressants. In addition, pathologic slides of these patients are proceeded to IHC stain for PLA2R (Atlas®). Clinical parameters and pathologic findings are collected for analyzed.


During the study period, totally 60 patients were diagnosed with membranous nephropathy. 58 patients received blood test for plasma anti-PLA2R, and 55 patients’ pathologic slide were successfully proceeded to IHC stain of podocyte PLA2R. Within patients receiving both evaluation (n=53), there are 24 patients with double positive results (45.3%), and 19 patients with double negative results (35.8%). 3 patients have plasma anti-PLA2R antibody but got negative results of podocyte PLA2R enhanced expression (5.7%). 7 patients have no plasma anti-PLA2R antibody but got positive results of podocyte PLA2R enhanced expression (13.2%). Discrepancy of serum ant-PLA2R and podocyte PLA2R expression account for totally 18.9% of enrolled patients.


The reason of discrepancy of serum ant-PLA2R and podocyte PLA2R expression is still not known yet. Further studies are still needed Currently, serum anti-PLA2R ELSIA assay and tissue IHC stain for PLA2R expression are both useful tools for diagnosis of PLA2R-assocaited membranous nephropathy.